Skip to main content
. 2023 Sep 12;5(1):vdad106. doi: 10.1093/noajnl/vdad106

Figure 1.

Figure 1.

Kaplan–Meier estimates of progression-free survival (A) and overall survival (B) in newly diagnosed unmethylated MGMT GBM patients treated with combined Sunitinib, Temozolomide and Radiotherapy. Patients were assessed from time of diagnosis to time of tumor progression clinically or by MR imaging as per RANO criteria.